pantoprazole has been researched along with Alloxan Diabetes in 1 studies
Pantoprazole: 2-pyridinylmethylsulfinylbenzimidazole proton pump inhibitor that is used in the treatment of GASTROESOPHAGEAL REFLUX and PEPTIC ULCER.
pantoprazole : A member of the class of benzimidazoles that is 1H-benzimidazole substituted by a difluoromethoxy group at position 5 and a [(3,4-dimethoxypyridin-2-yl)methyl]sulfinyl group at position 2.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Grong, E | 1 |
| Nord, C | 1 |
| Arbo, IB | 1 |
| Eriksson, M | 1 |
| Kulseng, BE | 1 |
| Ahlgren, U | 1 |
| Mårvik, R | 1 |
1 other study available for pantoprazole and Alloxan Diabetes
| Article | Year |
|---|---|
The effect of hypergastrinemia following sleeve gastrectomy and pantoprazole on type 2 diabetes mellitus and beta-cell mass in Goto-Kakizaki rats.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Combined Modality Therapy; Diabetes Mellitus, Expe | 2018 |